probenecid has been researched along with Parkinsonian Disorders in 15 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chronic administration of the compound, JZL184 (8 mg/kg), prevented MPTPp-induced motor impairment and preserved the nigrostriatal pathway." | 1.40 | Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. ( Aymerich, MS; Celorrio, M; Fernández-Suárez, D; Franco, R; González, H; Hillard, CJ; Oyarzabal, J; Pacheco, R; Riezu-Boj, JI; Ugarte, A, 2014) |
| " Chronic administration of MPTP/probenecid (MPTP/p) leads to oxidative stress, induction of apoptosis, and loss of dopominergic neurons which results in motor impairments." | 1.38 | Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease. ( Anandhan, A; Essa, MM; Manivasagam, T; Radhiga, T; Rao, S; Tamilselvam, K, 2012) |
| "Melatonin is a natural antioxidant and free radical scavenger that has been shown to effectively reduce cellular oxidative stress and protect mitochondrial functions in vitro." | 1.37 | Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease. ( Lau, YS; Patki, G, 2011) |
| "These results support reactive gliosis as a means of striatal compensation for dopamine loss." | 1.32 | Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. ( Beales, M; Dervan, AG; McBean, GJ; Meredith, GE; Meshul, CK; Moore, C; Snyder, AK; Totterdell, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xue, X | 1 |
| Zhang, W | 1 |
| Zhu, J | 1 |
| Chen, X | 1 |
| Zhou, S | 1 |
| Xu, Z | 1 |
| Hu, G | 1 |
| Su, C | 1 |
| Burks, S | 1 |
| Raymick, J | 1 |
| Robinson, B | 1 |
| Hanig, J | 1 |
| Sarkar, S | 1 |
| Selvakumar, GP | 1 |
| Janakiraman, U | 2 |
| Essa, MM | 3 |
| Justin Thenmozhi, A | 2 |
| Manivasagam, T | 3 |
| Fernández-Suárez, D | 1 |
| Celorrio, M | 1 |
| Riezu-Boj, JI | 1 |
| Ugarte, A | 1 |
| Pacheco, R | 1 |
| González, H | 1 |
| Oyarzabal, J | 1 |
| Hillard, CJ | 1 |
| Franco, R | 1 |
| Aymerich, MS | 1 |
| Bao, XQ | 1 |
| Wu, LY | 1 |
| Wang, XL | 1 |
| Sun, H | 1 |
| Zhang, D | 1 |
| Heng, Y | 1 |
| Zhang, QS | 1 |
| Mu, Z | 1 |
| Hu, JF | 1 |
| Yuan, YH | 1 |
| Chen, NH | 1 |
| Dhanalakshmi, C | 1 |
| Song, BJ | 1 |
| Guillemin, GJ | 1 |
| Alvarez-Fischer, D | 1 |
| Guerreiro, S | 1 |
| Hunot, S | 1 |
| Saurini, F | 1 |
| Marien, M | 1 |
| Sokoloff, P | 1 |
| Hirsch, EC | 1 |
| Hartmann, A | 1 |
| Michel, PP | 1 |
| Meredith, GE | 3 |
| Totterdell, S | 3 |
| Beales, M | 2 |
| Meshul, CK | 2 |
| Lau, YS | 3 |
| Patki, G | 2 |
| Das-Panja, K | 1 |
| Le, WD | 1 |
| Ahmad, SO | 1 |
| Luchtman, DW | 1 |
| Meng, Q | 1 |
| Song, C | 1 |
| Anandhan, A | 1 |
| Tamilselvam, K | 1 |
| Radhiga, T | 1 |
| Rao, S | 1 |
| Dervan, AG | 1 |
| McBean, GJ | 1 |
| Moore, C | 1 |
| Snyder, AK | 1 |
| Petroske, E | 1 |
| Callen, S | 1 |
15 other studies available for probenecid and Parkinsonian Disorders
| Article | Year |
|---|---|
Aquaporin-4 deficiency reduces TGF-β1 in mouse midbrains and exacerbates pathology in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Aquaporin 4; Astrocytes; Cel | 2019 |
Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson's disease mouse model: Endothelial and microglial effects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcarnitine; Animals; Astrocytes; Dopamine Plasma | 2019 |
Escin attenuates behavioral impairments, oxidative stress and inflammation in a chronic MPTP/probenecid mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport | 2014 |
Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model.
Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acids; Benzodioxoles; Corpus Striatum; Disease Models | 2014 |
Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzeneacetamides; Disease | 2015 |
Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Anti-Inflammatory Agents; Di | 2016 |
Chronic mild stress augments MPTP induced neurotoxicity in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Pharmaceutic; Animals; Body Weight; Brain-D | 2017 |
Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Pharmaceutic; Animals; Brain; Chromatograph | 2008 |
Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease.
Topics: Adjuvants, Pharmaceutic; Animals; Apoptosis; Autophagy; Biological Transport, Active; Disease Models | 2009 |
Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration.
Topics: Adjuvants, Pharmaceutic; Animals; Biomarkers; Brain-Derived Neurotrophic Factor; Corpus Striatum; Di | 2011 |
Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Free Radic | 2011 |
Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease.
Topics: Animals; Biogenic Monoamines; Brain; Cyclooxygenase 2; Cytokines; Eicosapentaenoic Acid; Exploratory | 2012 |
Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biflavonoids; Catechin; Dopaminergic Neurons; | 2012 |
Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biological Transport; Cell Count; | 2004 |
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Axons; Brain; Cell Death; Chro | 2001 |